EQUASENS (ex-Pharmagest Interactive): H1 2022 Revenue
Villers-lès-Nancy, 3 August 2022 - 6:00 p.m.
(CET)
PRESS RELEASE
H1 2022
Revenue
-
Up 10.3% to €103.57m.
-
Like-for-like (excl. the
PROKOV EDITIONS acquisition), Group revenue
grows 7.68% to €101.11m.
-
Gains by all Divisions (with the exception of FINTECH,
particularly affected by the economic context).
-
Effects of the French Digital Healthcare investment
programme (Ségur du Numérique
en
Santé):
-
Teams focused on submitting supplier certification
applications under the government
programme’s
timeline.
-
Q2 revenue growth
outpaces Q1: +11.48% vs. +9.03%. The
rollout of “Ségur” offerings to
be stepped up.
-
Full-year growth targets
confirmed.
(€m) |
H1 2021 |
H1 2022 |
Change2022/2021 |
Q1 |
45.27 |
49.36 |
+ 9.03 % |
Q2 |
48.63 |
54.21 |
+ 11.48 % |
Total H1 |
93.90 |
103.57 |
+ 10.30 % |
********
Equasens Group reported consolidated revenue of
€103.57m for the six-month period ending 30 June 2022, up 10.3%
year-on-year. Like-for-like (excluding the acquisition of PROKOV
EDITIONS), Group revenue grew 7.68% to €101.11m.
It should be noted that the new organisation,
effective from 1 January 2022, henceforth includes 5 Divisions:
- PHARMAGEST (formerly the Europe
Pharmacy Solutions Division);
- AXIGATE LINK (formerly the Health
and Social Care Facilities Solutions Division);
- E-CONNECT, responsible for
designing e-health solutions for healthcare professionals and the
well-being of dependent patients;
- MEDICAL SOFT, the new medical
software Division, which now includes the activities of PROKOV
EDITIONS;
- FINTECH.
This new organisation results in a marginal
change in the respective contributions of each Division to total
Group revenue.
H1 2022 business
highlights
- The PHARMAGEST
Division reported sales of €75.81m, up 6.77% from H1
2021.
This Division accounts
for 73.19% of total Equasens Group revenue.
-
France: +5.74% to €67.81m.
This Division
continues to perform well, bolstered by investment capacities of
pharmacists which continued to improve in 2021. The combined
contributions of the OFFITAG and ASCAETIQ offerings and the
restructuring of the latter's electronic labelling business also
contribute to this growth momentum.
-
Italy: +17.91% to €5.30m.
The investment plan
(recruitment campaigns, opening of new branches) is beginning to
produce results, both for pharmacies and wholesaler-distributors.
This Business Unit is continuing to grow at a sustained pace,
mainly in response to increased synergies with France, the launch
of the latest generation of id. software and the deployment of new
European products (id.TAG, id.LOCKER, id.EASYQ, etc.).
-
Belgium: +13.40% to €1.37m.
The situation is
improving, though remains fragile as pharmacists and pharmacy
groups are continuing to experience financial pressures impacting
their capacity to invest.
- Digital
Communications Business Unit: +13.38% to €1.32m.
The increased offering
of services for pharmacies, industry and pharmacy groups (for
example, the SAILFI loyalty programme) contributed to the growth in
revenue.
- The AXIGATE LINK
Division had sales of €15.14m, up 8.40% from
H1 2021.
This Division accounts
for 14.62% of total Equasens Group revenue.
After a more subdued
first quarter, all business sectors were up as commercial momentum
strengthened.
- Nursing
home sector: +7.80% to €7.68m.
In Belgium, MALTA
BELGIUM's nursing home business is steadily expanding, as it
prepares for the launch of the new multilingual cloud-based version
of the flagship software suite, TITANLINK.
-
Hospital-at-Home sector: +2.48%
to €2.67m.
Although marginally
impacted by the lead time for implementing the Ségur programme
(-12.44% in Q1), this Business Unit is now benefiting from the
qualification of its DOMILINK HAD software for this programme to
strengthen the deployment of its offerings (+17.34% in Q2).
- Hospital
sector: +7.74% to €2.14m.
The business
development process for hospital groups is long and complex. This
being said, the HOSPILINK solution’s very recent qualification for
the Ségur programme on 25 July 2022 is expected to have a
significant impact on open calls for tender as well as prospecting
activities addressing regional hospital networks.
- The
Healthcare Establishment and Private Practice sector:
+13.29% to €2.34m.
PANDALAB is continuing
to roll out pandaLAB Pro with more than 17,000 healthcare
professionals connected to this secure instant messaging
system.
-
Telemedicine sector: +68.16% to €0.31m.
While marginal (0.30%
of total revenue), the Group has made significant commitments to
support this Business Unit: signature of a remote monitoring
agreement for bariatric surgery patients with the Nancy Regional
and University Hospital Centre (CHRU), finalisation of a technical
partnership with MWS to equip the large majority of nursing homes
and manage CARELIB EHPAD notifications (fall detection and medical
alerts) "to the right people, on the right platform (in particular
the DECT mobile devices of nursing staff, but also within the
pandaLAB Pro and TITANLINK solutions) at the right time".
- The E-CONNECT
Division had sales of €9.08m, up 19.52% from H1 2021 and
accounting for 8.77% of Equasens Group revenue.
- For the
Frail Management activity, the business
development plan (test boxes in Germany, Belgium, France and the
Netherlands) combined with reinforced Communication/Marketing
efforts is starting to resonate with its market though without
making up for the Q1 lag.
- Growth momentum for
the Compliance and e-Connect
businesses have remained on track. The prime concern of the
e-Connect Business Unit continues to be anticipating sourcing needs
and ensuring the quality of electronic components in a market
expecting continuing tensions over the next few months.
- The MEDICAL SOFT
Division, which includes the PROKOV EDITIONS business,
reported sales of €2.46m, thereby confirming the justification for
this acquisition in Q4 2021.
This new Division
accounts for 2.37% of total Equasens Group revenue.
MédiStory 4, the
latest generation of the software developed for private
practitioners, was recently awarded Ségur certification from the
French Digital Health Agency based on meeting 155 functional
requirements. As a result, users of the different versions of
MédiStory (with 9,500 GPs and specialists equipped to date) are
eligible to subscribe to Ségur functions (complete migration of the
solution or functional extensions).
- The FINTECH
Division had sales of €1.09m, down 18.59% from H1
2021, and accounting for 1.05% of Equasens Group revenue.
Reflecting
unfavourable banking and financial sector trends, this business has
been impacted by rising interest rates and a corresponding increase
in lead times.
Significant events occurring after 30
June 2022
Equasens Group completes the majority
acquisitions of three companies(excerpt from press release
of 28 July 2022)
Therapeutic compliance is a key issue at the
European level in the management of elderly and chronically ill
patients. In 2022, continuing to implement a strategy focused on
patients and effective medication compliance, the Group has
increased its shareholdings in three of its European
subsidiaries:
- MULTIMEDS, an Irish
company which produces and distributes manual pill dispensers;
- CAREMEDS, a British
company, the developer of the eMAR traceability solution for
prescription drugs prepared in pill dispensers for use in
pharmacies and nursing homes;
- I-MEDS, a German
wholesaler and distributor of equipment and accessories for
supplying drugs to patients and pharmacies.
These different operations will help Equasens
Group accelerate its expansion and reinforce its presence in
several European countries. In particular:
- in the United
Kingdom, by combining CAREMEDS' eMAR medication traceability
solution with MALTA INFORMATIQUE's TITANLINK facility management
solution (MALTA intends to replicate its Business Model, based on
the successful example of MALTA BELGIUM in Belgium);
- in Germany, by
enhancing MULTIMEDS’ manual dispensing range with the Group's
pharmacy automation solutions, and in particular the addition of
AUTOMEDS' semi-automatic dispensing systems, which are perfectly
suited to the German market in terms of design and capacity.
The
Ségur
qualified HOSPILINK
solution
Following the success of MédiStory 4 (a software
suite for physicians from the MEDICAL SOFT Division) and DOMILINK
HAD (a Hospital at Home solution from the AXIGATE LINK Division),
on 25 July 2022 Equasens Group announced HOSPILINK’s qualification
in the Hospital category for the Ségur investment programme.
Developed by AXIGATE teams, this application addresses the needs of
hospitals, regional hospital groups, specialised, post-acute and
rehabilitation facilities (AXIGATE LINK Division).
In line with the validation procedures (DSR or
Dossier de Spécifications de Référencement or Software
Specification Requirements), French Digital Health Agency (Agence
du Numérique en Santé or ANS) teams ensured that the software
complied with the technical, functional and ergonomic
specifications. During its review of the HOSPILINK application, the
ANS certification board noted that "the management of data and
compliance with the procedures of the core services (were) carried
out within an application framework provided reasonable guarantees
with respect to compliance with the specifications and compliance
scenarios as issued".
This qualification - the 3rd in 2 months for
Equasens Group - was awarded within the framework of the Electronic
Medical Records (EMR) category for the profiles:
- Hospital - EMR:
General
- Hospital - EMR: Patient Health ID
integration
- Hospital - EMR: Web client
EMR.
2022 outlook
After a slower first quarter, the pace of growth
picked up in Q2 and Equasens Group confirms its goal of maintaining
this momentum for the full year.
In this context, funding provided by the public
authorities through the French Digital Healthcare programme (Ségur
du Numérique en Santé) should facilitate and even accelerate sales
of the Group’s software extensions. The Group in consequence
intends to manage Ségur projects while continuing to develop its
other specialised activities (the Digital Health Gateway, the
NOVIAcare programme, e-health technological solutions, etc.), which
have made Equasens Group a key player in the healthcare
ecosystem.
Financial calendar:
New dates for the communication of
half-year results:
- Publication of H1 results:
Thursday 22 September 2022 (after the close of
trading).
- Presentation of H1 results:
Friday 23 September 2022 at 11:30 am in
Paris.
- Publication of Q3 2022
revenue: 9 November 2022 (after the close of trading).
About Equasens
Group:
With more than 1,200 employees fulfilling a
vital role as “Citizens in the Service of Health and Well-Being”,
Equasens Group is today a key player in the European healthcare
sector, providing software solutions to all healthcare
professionals (pharmacists, primary care practitioners, hospitals,
Hospital-at-Home structures, retirement homes, health centres) in
both primary and secondary care sectors.
With operations in France, Italy, Belgium,
Luxembourg, the United Kingdom and Germany, Equasens Group is
currently developing the leading healthcare platform and a unique
ecosystem in France and Europe benefiting people by making
available the very best of technology.
Listed on Euronext Paris™ - Compartment A
Included in the Euronext Tech Leaders segment
and the European Rising Tech label Indexes: MSCI GLOBAL SMALL CAP -
GAÏA Index 2020 - CAC® SMALL and CAC® All-Tradable
Eligible for the Deferred Settlement Service (“Service à
Réglement Différé” - SRD) and equity savings accounts invested in
small and mid caps (PEA-PME).ISIN: FR0012882389 - Ticker
Code: EQS
For all the latest news on Equasens Group go to
www.equasens.com
CONTACTS
Analyst and Investor
Relations: Chief Administrative and Financial Officer :
Jean-Yves SAMSONTel. +33 (0) 83 15 90 67 -
jean-yves.samson@equasens.com
Media Relations:
FIN’EXTENSO - Isabelle APRILE
Tel. +33 (0)1 39
97 61 22 - i.aprile@finextenso.fr
- EQUASENS_PRESSRELEASE_20220803_H1 2022 REVENUE_en_US
Equasens (EU:EQS)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Equasens (EU:EQS)
Historical Stock Chart
Von Apr 2023 bis Apr 2024